Attorney Docket No.: 03678.0103.CPUS00

when  $G_5 = C(CHOJ_{15})$  and  $G_6 = CHCH_2(OJ_{19})$ ,  $J_{15}$  and  $J_{19}$  optionally are bonds from the oxygen atoms of  $G_5$  and  $G_6$ , respectively, to a carbon atom of an acetal , ketal or orthoester group  $G_{11}$ ; wherein  $G_{11} = Q_1(T_1)(T_2)$ ; or

when  $G_1 = CH(OJ_1)$  and  $G_6 = CH(CH_2OJ_{19})$  or  $CH(OJ_{19})$ ,  $J_1$  and  $J_{19}$  are optionally bonds from the oxygen atoms of  $G_1$  and  $G_6$ , respectively, to a carbon atom of an acetal-, ketal- or orthoester group  $G_{12}$ ;

wherein  $G_{12} = Q_1(T_1)(T_2)$ ;

wherein Q<sub>+</sub> is a carbon atom; and

T<sub>1</sub> = H, CF<sub>3</sub>, alkyl, cycloalkyl, arylalkyl or aryl;

T<sub>2</sub> = H, OT<sub>3</sub>, CF<sub>3</sub>, alkyl, cycloalkyl, arylalkyl, aryl or heterocycle of 5 to 7 members;

 $T_3$  = alkyl, cycloalkyl, arylalkyl or aryl; or

T<sub>1</sub> and T<sub>2</sub>, when taken together, form a carbocyclic ring of 5 or 6 members, with or without unsaturation and with or without substitution; or

Q<sub>1</sub>(T<sub>1</sub>)(T<sub>2</sub>) is taken together to form a carbonyl, such that a cyclic carbonate is formed.

2. (Currently Amended) The method according to Claim 1, wherein:

 $X_1 = 0$ , NR, S; or

X<sub>1</sub> represents a bond from the pyrimidine ring to R<sub>4</sub>;

 $X_2 = H, F, Cl, Br, I, CF_3$ , alkyl, cycloalkyl, arylalkyl, arylalkenyl, arylalkynyl,  $C(O)OR_{17}$ ,  $C(O)NR_{16}R_{18}$  or heterocycle of 5 to 7 members;

 $X_3 = H, CN, C(O)OR_{33};$ 

R = H, alkyl, cycloalkyl, arylalkyl, aryl;

 $Y_1 = 0$ ; or

Y<sub>1</sub>-represents a bond from the point of ring attachment to M<sub>1</sub>;

 $Y_2 = 0$ ; or

Y<sub>2</sub>-represents a bond from the point of ring attachment to M<sub>2</sub>;

M<sub>3</sub> = alkyl, cycloalkyl, arylalkyl, or aryl;

 $M_4$  = alkyl, cycloalkyl, arylalkyl or aryl;

A<sub>1</sub> = H, alkyl, cycloalkyl, arylalkyl or aryl;

A<sub>2</sub> - H, alkyl, cycloalkyl, arylalkyl, aryl or heterocycle of 5 to 7 members; or

Attorney Docket No.: 03678.0103.CPUS00

where  $A_1$  and  $A_2$ , when taken together, form a carbocyclic ring of 5 or 6 members, with or without unsaturation, and with or without substitution; or

 $M_1Q(A_1)(A_2)M_2$  is taken together to form a carbonyl bonded to  $Y_1$  and  $Y_2$ , such that a cyclic carbonate is formed;

Z = O,  $CH_2$ ,  $CF_2$ , or  $CCl_2$ ;

 $G_2 = CH$ ,  $C(CH_2OJ_3)$ , or  $C(CO_2J_4)$ ;

 $J_3 = alkyl \text{ or } C(O)J_2$ ;

 $J_4 = alkyl;$ 

 $J_5 = H$ , alkyl or  $C(O)J_6$ ;

 $J_7 = H_{, or alkyl;}$ 

 $J_9 = H$ , alkyl or  $C(O)J_{10}$ ;

 $J_{13} = H$ , alkyl, or  $C(O)J_{14}$ ;

 $J_{15} = H$ , alkyl, or  $C(O)J_{16}$ ;

 $J_{17} = H$ , alkyl, or  $C(O)J_{18}$ ;

 $J_{21} = H$ , alkyl,  $C(O)J_{22}$  or heterocyclic ring of 5 to 7 members;

 $T_{+}$  = H, alkyl, or arylalkyl;

T<sub>2</sub> = H, alkyl, arylalkyl, or heterocycle of 5 to 7 members; or

T<sub>1</sub> and T<sub>2</sub>, when taken together, form a carbocyclic ring of 5 or 6 members, with or without unsaturation and with or without substitution; or

 $Q_1(T_1)(T_2)$  is taken together to form a carbonyl, such that a cyclic carbonate is formed.

3. (Currently Amended) The method according to Claim 2, wherein:

 $X_1 = 0$ , NR, S;

X<sub>2</sub> = H, F, Cl, Br, I, CF<sub>3</sub>, alkyl, arylalkyl, arylalkenyl, arylalkynyl, or heterocycle of 5 to 7 members;

 $X_3 = H$ 

R = H, alkyl, cycloalkyl, arylalkyl, aryl;

R<sub>4</sub> = H, alkyl, cycloalkyl, arylalkyl, aryl, or C(O)R<sub>5</sub>;

R<sub>5</sub> is H, alkyl, cycloalkyl, arylalkyl, aryl or heterocyclic ring of 5 to 7 members;

Attorney Docket No.: 03678.0103.CPUS00

```
E<sub>1</sub> and E<sub>2</sub> are H;
Y_1 = 0
Y_2 = 0
M<sub>1</sub> and M<sub>2</sub> are independently H, alkyl, cycloalkyl, arylalkyl, aryl, C(O)M<sub>3</sub>,;
M<sub>3</sub> = alkyl, cycloalkyl, arylalkyl, or aryl;
A<sub>+</sub> = H, alkyl, cycloalkyl, arylalkyl or aryl;
A_2 = H, alkyl, cycloalkyl, arylalkyl, or aryl;
Z = O, CH_2, CF_2, or CCl_2;
G_1 = 0 or S:
G_2 - CH;
G_3 = CH_2, CH(OJ_5) or CH(NJ_6J_7) CH(OH), or CH(NHJ_7);
G_4 = CH_2, CH(OJ_9), or CH(NJ_{11}J_{13}) CH(OH), or CH(NHJ_{13});
G_5 = CH_2, CH(OJ_{15}), or CH(NJ_{16}J_{17}); CH(OH), or CH(NHJ_{17});
G_6 = CH_2, CH(CH_3), CH(OJ_{19}), CH(CH_2OJ_{19}), CH(CH_2(NJ_{21}J_{23})), or
CH(CO_2J_{21}), with the provision that when G_1 = O or S, then G_6 does not equal CH(OH); and
the number of hydrogen atoms bonded to the G<sub>1</sub>-G<sub>6</sub>-ring atoms is limited to a maximum of 8;
also with the provision that the number of nitrogen atoms bonded to the G<sub>1</sub>-G<sub>6</sub> ring atoms in
Formula I is limited to a maximum of 2;
J<sub>6</sub>, J<sub>11</sub>, and J<sub>16</sub> are independently H, alkyl, arylalkyl, or aryl;
J_5 = H, alkyl or C(O)J_6;
J_7 = H, or alkyl;
J_9 = H, alkyl or C(O)J_{10};
J_{13} = H, alkyl, or C(O)J_{14};
J_{15} = H, alkyl, or C(O)J_{16};
J_{12} = H, alkyl, or C(O)J_{18};
J_{19} = H, alkyl, or C(O)J_{20};
J_{21} = H, alkyl, or C(O)J_{22}; and
J_{23} = H, alkyl, or C(O)J_{24}.
```

Attorney Docket No.: 03678.0103.CPUS00

4. (Original) The method according to Claim 1, wherein said method further comprises the step of measuring the intraocular pressure of said subject before administering the composition.

- 5. (Original) The method according to Claim 1, further comprising the step of measuring the intraocular pressure of said subject after administering the composition.
- 6. (Original) The method according to Claim 1, wherein administering said pharmaceutical composition to said subject is to treat ocular hypertension.
- 7. (Original) The method according to Claim 6, wherein administering said pharmaceutical composition to said subject is to treat glaucoma.
- 8. (Original) The method according Claim 1, wherein said pharmaceutical composition is co-administered to said subject with other therapeutic agent or adjuvant therapy commonly used to reduce intraocular pressure.
- 9. (Original) The method according to Claim 1, wherein said pharmaceutical composition is administered topically to said subject.
- 10. (Original) The method according to Claim 1, wherein said pharmaceutical composition is administered via subconjunctival, subscleral, or intravitreal injection to said subject.

# 11. (Withdrawn) A compound according to Formula IA:

#### Formula IA

$$G_5$$
 $G_6$ 
 $G_7$ 
 $G_8$ 
 $G_8$ 
 $G_9$ 
 $G_9$ 

wherein:

 $R_4$  = alkyl, cycloalkyl, arylalkyl, aryl, heterocyclic ring of 5 to 7 members,  $C(O)R_5$ ,  $C(O)OR_6$  or  $C(O)NR_5R_7$ ;

 $X_1, X_2, X_3, R, R_1-R_3, R_5-R_{35}, E, E_1, E_2, Y_1, Y_2, M_1-M_5, A_1-A_3, Z, Z_1-Z_3, G_1-G_6, J_1-J_{24}, G_1-G_{12}, T_1-T_3$  are the same as those described in Formula I in Claim 1.

### 12. (Withdrawn) A compound of Formula IB:

#### Formula IB

$$G_5$$
 $G_6$ 
 $G_1$ 
 $G_4$ 
 $G_3$ 
 $G_2$ 
 $G_4$ 
 $G_3$ 
 $G_4$ 
 $G_4$ 
 $G_3$ 
 $G_4$ 
 $G_5$ 
 $G_6$ 
 $G_7$ 
 $G_8$ 
 $G_8$ 
 $G_9$ 
 $G_9$ 

wherein:

 $X_2$ ,  $X_3$ , R,  $R_1-R_3$ ,  $R_5-R_{35}$ , E,  $E_1$ ,  $E_2$ ,  $Y_1$ ,  $Y_2$ ,  $M_1-M_5$ ,  $A_1-A_3$ , Z,  $Z_1-Z_3$ ,  $G_1-G_6$ ,  $J_1-J_{24}$ ,  $G_1-G_{12}$ ,  $T_1-T_3$  are the same as those described in Formula I in Claim 1;

provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,

 $G_2 = CH$ ,  $G_3 = CH(OJ_5)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$  and  $G_6 = CH(CH_2OJ_{19})$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_5$ ,  $J_9$ ,  $J_{15}$ , or  $J_{19}$  is not equal to H.

### 13. (Withdrawn) A compound of Formula IC:

#### Formula IC:

$$G_{5}$$
 $G_{6}$ 
 $G_{1}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{1}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{1}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{4}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{4}$ 
 $G_{3}$ 
 $G_{4}$ 
 $G_{5}$ 
 $G_{5}$ 
 $G_{7}$ 
 $G_{7$ 

wherein

 $X_2$ ,  $X_3$ , R,  $R_1-R_3$ ,  $R_5-R_{35}$ , E,  $E_1$ ,  $E_2$ ,  $Y_1$ ,  $Y_2$ ,  $M_1-M_5$ ,  $A_1-A_3$ , Z,  $Z_1-Z_3$ ,  $G_1-G_6$ ,  $J_1-J_{24}$ ,  $G_1-G_{12}$ ,  $T_1-T_3$  are the same as those described in Formula I in Claim 1;

provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = O$ ,  $G_1 = O$  or CH(OH),  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OJ_5)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$  and  $G_6 = CH(CH_2OJ_{19})$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_5$ ,  $J_9$ ,  $J_{15}$ , or  $J_{19}$  is not equal to H;

further provided that when  $X_2 = H$  or  $CH_2OH$ ,  $E = Y_1 = Z = Z_1 = Z_2 = G_1 = O$ ,  $Y_2 = bond$  to  $M_2$  from ring,  $E_1 = E_2 = M_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OJ_5)$  and  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_2OJ_{19})$ , then at least one of  $X_3$ ,  $M_1$ ,  $J_5$ ,  $J_9$ ,  $J_{15}$ , or  $J_{19}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OJ_5)$ ,  $G_4 = CH_2$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_3)$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_5$ , or  $J_{15}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH_2$  or  $CH(NH_2)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_3)$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_9$ , or  $J_{15}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(NH_2)$ ,  $G_4 = CH(OJ_9)$ ,  $G_5 = CH(OJ_{15})$ ,  $G_6 = CH(CH_2(NH_2))$ , then at least one of  $X_2$ ,  $X_3$ ,  $M_1$ ,  $M_2$ ,  $J_9$ , or  $J_{15}$  is not equal to H;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OH)$ ,  $G_4 = CH_2$ ,  $G_6 = CH(CH_3)$ , then  $G_5$  is not equal to CHF;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = X_2 = X_3 = M_1 = M_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OH)$ ,  $G_4 = CH(OH)$ ,  $G_5 = CH(OH)$ , then  $G_6$  is not  $CH(CH_3)$  or  $CH(CHF_2)$ ;

further provided that when  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $E_1 = E_2 = H$ ,  $G_2 = CH$ ,  $G_3 = CH(OH)$ ,  $G_5 = CH(OH)$ ,  $G_6 = CH(CH_2OH)$  then  $G_4$  is not CHF.

Attorney Docket No.: 03678.0103.CPUS00

# 14. (Withdrawn) A compound of Formula ID:

## Formula ID

$$G_5$$
 $G_4$ 
 $G_3$ 
 $G_2$ 
 $G_4$ 
 $G_3$ 
 $G_2$ 
 $G_4$ 
 $G_3$ 
 $G_4$ 
 $G_4$ 
 $G_4$ 
 $G_5$ 
 $G_4$ 
 $G_5$ 
 $G_4$ 
 $G_5$ 
 $G_7$ 
 $G_8$ 
 $G_9$ 
 $G_9$ 

wherein:

 $X_3$  = CN, OR<sub>19</sub>, SR<sub>19</sub>, NR<sub>23</sub>R<sub>28</sub>, CF<sub>3</sub>, alkyl, cycloalkyl, C(O)R<sub>32</sub>, C(O)OR<sub>33</sub>, C(O)NR<sub>34</sub>R<sub>35</sub>, arylalkyl, aryl, arylalkenyl, arylalkynyl, or a heterocycle of 5 to 7 members;  $X_2$ ,  $X_3$ , E, E<sub>1</sub>, E<sub>2</sub>,  $Y_1$ ,  $Y_2$ , M<sub>1</sub>, M<sub>2</sub>, Z, Z<sub>1</sub>, Z<sub>2</sub>, and G<sub>1</sub>–G<sub>6</sub> are the same as those described in Formula I in Claim 1.

15. (Withdrawn) A compound of Formula IE:

#### **FORMULA IE**

$$G_5$$
 $G_6$ 
 $G_6$ 
 $G_7$ 
 $G_8$ 
 $G_9$ 
 $G_9$ 

wherein:

 $X_2$ ,  $X_3$ ,  $E_1$ ,  $E_2$ ,  $Y_1$ ,  $Y_2$ ,  $M_1$ ,  $M_2$ , Z,  $Z_1$ ,  $Z_2$ ,  $G_2$ – $G_6$  and  $J_1$  are the same as those described in Formula I in Claim 1.

Attorney Docket No.: 03678.0103.CPUS00

# 16. (Withdrawn) A compound of Formula IF:

# Formula IF

$$G_5$$
 $G_4$ 
 $G_3$ 
 $G_2$ 
 $G_4$ 
 $G_3$ 
 $G_2$ 
 $G_4$ 
 $G_3$ 
 $G_4$ 
 $G_4$ 
 $G_4$ 
 $G_5$ 
 $G_4$ 
 $G_5$ 
 $G_4$ 
 $G_5$ 
 $G_7$ 
 $G_8$ 
 $G_8$ 
 $G_9$ 
 $G_9$ 

wherein:

 $X_2$ ,  $X_3$ ,  $E_1$ ,  $E_2$ ,  $Y_2$ ,  $M_2$ , Z,  $Z_1$ ,  $Z_2$ ,  $G_2$ – $G_6$  are the same as those described in Formula I; Provided that when  $X_2 = CH_3$ ,  $X_3 = E_1 = E_2 = M_2 = H$ ,  $E = Y_2 = Z = Z_1 = Z_2 = G_1 = O$ ,  $G_2 = CH$ ,  $G_3 = G_4 = G_5 = CH(OH)$ , then  $G_6$  is not  $CH(CH_3)$  or  $CH(CH_3)$  or  $CH(CH_2OH)$ .

# Formula IG

$$G_{5}$$
 $G_{4}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{1}$ 
 $G_{2}$ 
 $G_{2}$ 
 $G_{1}$ 
 $G_{2}$ 
 $G_{2}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{4}$ 
 $G_{3}$ 
 $G_{2}$ 
 $G_{4}$ 
 $G_{5}$ 
 $G_{5}$ 
 $G_{6}$ 
 $G_{7}$ 
 $G_{7$ 

# wherein:

 $X_2$  is aryl, arylalkyl, arylalkynyl,  $C_2$ - $C_8$  alkyl,  $C_2$ - $C_8$  alkenyl, alkynyl, cycloalkyl, or  $C_3$ - $C_8$  branched alkyl, and none of the alkyl groups in  $X_2$  are substituted with an amine or an amide on the chain, or contain a nitrogen hetero atom;

 $X_3$ ,  $E_1$ ,  $E_2$ ,  $M_1$ ,  $M_2$ ,  $Y_1$ ,  $Y_2$ , Z,  $Z_1$ ,  $Z_2$ ,  $G_1$ - $G_6$  are the same as those described in Formula I in Claim 1.

# 17. (Withdrawn) A compound of Formula IH:

# Formula IH

wherein:

 $X_2$ ,  $X_3$ , E,  $E_1$ ,  $E_2$ ,  $M_1$ ,  $M_2$ ,  $Y_1$ ,  $Y_2$ , Z,  $Z_1$ ,  $Z_2$ ,  $G_2$ - $G_5$  and  $J_{21}$  are the same as those described in Formula I in Claim 1;

provided that when  $X_2 = X_3 = E_1 = E_2 = M_1 = M_2 = H$ ,  $E = Y_1 = Y_2 = Z = Z_1 = Z_2 = O$ ,  $G_2 = CH$ ,  $G_3 = G_4 = G_5 = CH(OH)$ , then  $J_{21}$  is not H or  $CH_3$ .

Attorney Docket No.: 03678.0103.CPUS00

### 18. (Withdrawn) A compound of Formula II:

#### Formula II

$$G_5$$
 $G_6$ 
 $G_1$ 
 $G_2$ 
 $G_3$ 
 $G_2$ 
 $G_4$ 
 $G_3$ 
 $G_4$ 
 $G_3$ 
 $G_4$ 
 $G_4$ 
 $G_4$ 
 $G_5$ 
 $G_4$ 
 $G_5$ 
 $G_4$ 
 $G_5$ 
 $G_6$ 
 $G_7$ 
 $G_8$ 
 $G_8$ 
 $G_9$ 
 $G_9$ 

wherein:

 $X_2$ ,  $X_3$ , E,  $E_1$ ,  $E_2$ ,  $A_1$ ,  $A_2$ , Z,  $Z_1$ ,  $Z_2$  and  $G_2$ - $G_6$  are the same as those described in Formula I in Claim 1;

provided that when  $X_2 = X_3 = E_1 = E_2 = H$ , and  $E = Z_1 = Z_2 = G_1 = O$ , and  $A_1 = A_2 = CH_3$ , then Z is not equal to  $CH_2$  or  $CF_2$ ;

further provided that when  $X_2 = X_3 = E_1 = E_2 = H$ , and  $E = Z = Z_1 = Z_2 = G_1 = O$ , and  $A_1$  and  $A_2$  are taken together to form an unsaturated 6-membered ring, then  $G_6$  is not CH(CH<sub>2</sub>OH).

- 19. (New) The method according to Claim 1, wherein said compound is uridine 5'-diphospho- $\alpha$ -glucose.
- 20. (New) The method according to Claim 1, wherein said compound is uridine 5'-diphospho- $\alpha$ -galactose.

21. (New) The method according to Claim 1, wherein said compound is uridine 5'-

diphospho-N-acetylglucosamine.